



Rule Category:
Pharmaceutical

Ref: No:
2022-PH-13

Version Control:
Version No. V1.1

Effective Date:
15th September 2022

Last Update:
23 May 2023



Nusirensen Indication

Adjudication Guideline (External instruction)

Table of content

| | | | | |
|---------------------------|-----------------------|-------------------------------------|-------------------------------|-----------------------------|
| Abstract Page 1 | Scope Page2 | Adjudication Policy Page2 | Denial codes Page 3 | Appendices Page 3 |
|---------------------------|-----------------------|-------------------------------------|-------------------------------|-----------------------------|

Abstract

For Members

Nusirensen is an Antisense drug approved by the FDA for the treatment of spinal muscular atrophy.

Spinal muscular atrophy (SMA) is a genetic (inherited) neuromuscular disease that causes muscles to become weak and waste away.

Nusirensen is available in injection form and is administered intrathecal, or an injection into the fluid of the spine.

For Medical Professionals

Nusirensen is an antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Spinal muscular atrophy (SMA) is a genetic (inherited) neuromuscular disease that causes muscles to become weak and waste away.

People with SMA are either missing part of the SMN1 gene on chromosome 5q or have a changed (mutated) gene. A healthy SMN1 gene produces SMN protein. People with SMA don't make enough SMN protein and lose a specific type of nerve cell in the spinal cord (called motor neurons) that control muscle movements.

Nusirensen is an intrathecal injection, or an injection into the fluid of the spine, by a healthcare professional experienced in performing lumbar punctures.

Approved by:
Daman

Responsible:
Medical Standards & Research

Related Adjudication Guidelines: NA

Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by the National Health Insurance Company – Daman PJSC (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and always remains the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed, or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one-month prior notice.

PUBLIC

National Health Insurance Company – Daman (PJSC) (P.O. Box 128888, Abu Dhabi, U.A.E. Tel No. +97126149555 Fax No. +97126149550)

| | | | | | | | | | |
|---------------|----------|--------------|---|---------------|---|----------------|------------|--------------|--------|
| Doc Ctrl No.: | TEMP/349 | Version No.: | 1 | Revision No.: | 1 | Date of Issue: | 16.07.2019 | Page No(s).: | 1 of 4 |
|---------------|----------|--------------|---|---------------|---|----------------|------------|--------------|--------|

Scope

This Adjudication Rule highlights the medical indications and coverage requirements of Nusirensen for spinal muscular atrophy for all health insurance plans administered by Daman as per policy terms and conditions.

Medical Indications:

Nusirensen is an antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Different Types of SMA

Type 1 SMA (young babies)

is the most common and severe form of SMA. It's sometimes called Werdnig-Hoffmann disease or infantile-onset SMA and it typically presents after birth but before age six months.

Type 2 SMA (older babies and toddlers)

is an intermediate form of SMA and shows symptoms when they're 6 to 18 months old.

Type 3 SMA (children and young adults)

is a milder form of SMA. It's also known as Kugelberg-Welander disease, and its Onset usually occurs between the age of 18 months and adulthood.

Type 4 SMA (adults)

is very rare. It usually starts in young adulthood and causes mild motor impairment.

Type 0 SMA (prenatal onset)

A very severe form of SMA, prenatal onset and is usually associated with early death from respiratory failure.

A pre-symptomatic SMA patient individual is defined as having the homozygous gene deletion or homozygous mutation, or compound heterozygous mutation of the SMN1 gene (Chromosome 5) found via pre-symptomatic testing of the patient. These patients are genetically destined to develop 5q SMA.

• Adjudication Policy

Eligibility / Coverage Criteria

- Type I, II, III, and pre-symptomatic
- Confirmed genetic documentation of 5q SMA homozygous gene deletion or homozygous mutation, deletion, or compound heterozygous mutation.
- Age of the member is 15 years or younger at the start of the treatment.
- Must be prescribed by a neurologist.
- Must not be type 0 and type IV SMA patient.
- No permanent ventilation (≥ 16 hours/day for 21 consecutive days in the absence of acute reversible infection) or permanent tracheostomy status.
- Member has not received gene replacement therapy previously for SMA (Ex: Zolgensma) or received gene replacement therapy earlier but worsened in clinical status.
- Nusirensen is not prescribed concurrently with Evrysdi or Zolgensma
- Should provide one of the following assessment tools as indicated by the patient motor ability:

1) Hammersmith Infant Neurological Exam part-2 (HINE-2) or

PUBLIC

- 2) Hammersmith Functional Motor Scale Expanded (HFSME) or
- 3) Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND).
- 4) Revised Upper Limb Module (RULM)

Criteria for continuation of treatment

- I. All the above criteria are met.
- II. Initial evaluation should be done after 5 doses (4 loadings and 1 maintenance dose) and the member should show a positive clinical response from pre-treatment baseline to nusirensen treatment as demonstrated by at least one of the following assessments:
 - A. **HINE:** Member shows improvement of at least:
 - i. 2 points horizontal kick or
 - ii. 1 point on other HINE scores (Ex: rolling, crawling, sitting, standing, head control, or walking) excluding voluntary grasp.
 - B. **HFSME:** improvement of at least 3 points.
 - C. **CHOP INTEND:** Member should exhibit at least 4 points of improvement on this scale.
 - D. **RULM:** At least a 2-point increase in score from pre-treatment baseline.
- III. 12month periodic re-examination must be done.

Non-Coverage

Off-label uses of Nusirensen that are not an FDA-approved indication or not included in the 'Coverage Criteria' section of this policy is considered experimental/investigational or not a covered benefit of this policy.

| Plan | Coverage |
|---------------|--------------------|
| Visitor plan | Not covered |
| Basic plan | Not covered |
| Enhanced plan | Covered as per SOB |
| Thiqa | Covered |

| Eligible clinician specialty |
|---|
| Neurosurgery |
| Neurology |
| Pediatric Neurology |
| Neurological Surgery |
| Clinical Neurophysiology |
| Pediatric Neurology/ Clinical Neurophysiology |

Payment and Coding Rules

Kindly apply DOH payment rules and regulations and relevant coding manuals for ICD, Drugs.

PUBLIC

National Health Insurance Company – Daman (PJSC) (P.O. Box 128888, Abu Dhabi, U.A.E. Tel No. +97126149555 Fax No. +97126149550)

| | | | | | | | | | |
|---------------|----------|--------------|---|---------------|---|----------------|------------|--------------|--------|
| Doc Ctrl No.: | TEMP/349 | Version No.: | 1 | Revision No.: | 1 | Date of Issue: | 16.07.2019 | Page No(s).: | 3 of 4 |
|---------------|----------|--------------|---|---------------|---|----------------|------------|--------------|--------|

Denial codes

| Code | Code description |
|----------|---|
| MNEC-003 | Service is not clinically indicated based on good clinical practice |
| MNEC-005 | Service/ supply may be appropriate, but too frequent. |
| CLN-001 | Activity/diagnosis inconsistent with clinician specialty |
| NCOV-003 | Service(s) is (are) not covered |
| Auth-001 | Prior approval is required and was not obtained |

Kindly use the below Pre-Approval Form for Authorization:

https://www.damanhealth.ae/main/pdf/support/Questionnaire/NUSIRENSEN_QUESTIONNAIRE.pdf

Appendices

References

- https://www.spinraza.com/content/dam/commercial/spinraza/caregiver/en_us/pdf/spinraza-prescribing-information.pdf
- <https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza>
- <https://www.nhs.uk/conditions/spinal-muscular-atrophy-sma/types/>
- <https://www.uptodate.com/contents/spinal-muscular-atrophy>
- <https://www.nhs.uk/conditions/spinal-muscular-atrophy-sma/diagnosis/>
- Spinraza 12 mg solution for injection - Summary of Product Characteristics (SmPC) - (emc) (medicines.org.uk)
- <https://www.nice.org.uk/guidance/ta588/resources/managed-access-agreement-july-2019-pdf-6842812573><https://www.nice.org.uk/guidance/ta588/resources/managed-access-agreement-july-2019-pdf-6842812573>
- https://www.spinraza-hcp.com/content/dam/commercial/spinraza/hcp/en_us/pdf/mobility-and-physical-ability.pdf

I. Revision History

| Date | Change(s) |
|------------------------------|-----------------------------|
| 15 th August 2022 | Release of V1.0 |
| 23 rd May 2023 | Updated: questionnaire link |

PUBLIC

National Health Insurance Company – Daman (PJSC) (P.O. Box 128888, Abu Dhabi, U.A.E. Tel No. +97126149555 Fax No. +97126149550)

| | | | | | | | | | |
|---------------|----------|--------------|---|---------------|---|----------------|------------|--------------|--------|
| Doc Ctrl No.: | TEMP/349 | Version No.: | 1 | Revision No.: | 1 | Date of Issue: | 16.07.2019 | Page No(s).: | 4 of 4 |
|---------------|----------|--------------|---|---------------|---|----------------|------------|--------------|--------|